Robert
Pacifici, CHDI's Chief Scientific Officer, stated,
"We are intrigued with the potential that Samaritan's
neuroprotective drugs have in combating Huntington's
disease and look forward to evaluating the Company's
portfolio of Alzheimer's drugs. CHDI is dedicated
to researching therapies that could help Huntington's
disease patients and our team looks forward to the
collaboration with Samaritan.''
About
Huntington's Disease
Huntington's
disease is a familial disease, passed from parent
to child through a mutation in a gene. Each child
of an HD parent has a 50-50 chance of inheriting the
HD gene, which causes programmed degeneration of brain
cells and results in emotional disturbance, loss of
intellectual faculties and uncontrolled movements.
Most people with HD develop the symptoms at midlife
but in some people onset occurs in infancy or old
age. The average survival time after onset is approximately
fifteen to twenty years. It is estimated that about
one in every 10,000 persons has the HD gene. At this
time, there is no way to stop or reverse the course
of HD.
About
CHDI Foundation, Inc.
CHDI
Foundation, Inc. is a non-profit organization pursuing
a biotech approach to rapidly discover and develop
drugs that prevent or slow Huntington's disease. Through
collaborations with academic and industrial partners,
CHDI participates in all aspects of drug discovery
and development from discovery research through clinical
development.
About
Samaritan Pharmaceuticals
Samaritan
Pharmaceuticals: "Transforming Today's Science
Into Tomorrow's Cures...''
Samaritan
Pharmaceuticals is an entrepreneurial biopharmaceutical
company committed to bringing innovative life-saving
drugs to suffering patients.
Website:
http://www.samaritanpharma.com
Please register so we can notify you of upcoming conference
calls, news and events.
Disclaimer
The company disclaims any information created
by an outside party and endorses only information
communicated by its press releases, filings, and website.
This news release contains forward-looking statements
that reflect management's current beliefs about the
potential for its drug candidates, science, and technology.
However, as with any biopharmaceutical under development,
there are significant risks and uncertainties in the
process of development and regulatory review. There
are no guarantees that products will prove to be commercially
successful. For additional information about the factors
that affect the company's business, please read the
company's latest Form 10-Q filed November 19, 2007.
The company undertakes no duty to update forward-looking
statements.
Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
Erica Ruderman
Rachel Colgate
(212) 825-3210
